Swiss drugmaker Novartis AG is close to acquiring U.S. biotech Avidity Biosciences for over $70 per share, Bloomberg News reported on Sunday, citing a person familiar with the matter.
Reuters could not immediately confirm the report.
Reporting by Dheeraj Kumar in Bengaluru; Editing by Aidan Lewis
Kayla Webster
Source link